![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Memorial Sloan-Kettering Cancer Center |
Information provided by: | Memorial Sloan-Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT00582270 |
The purpose of this study is to determine if an infectious disease may be associated with the new lymphoma diagnosis.
Infections to be tested include:
Condition |
Indolent Non-Hodgkin's Lymphoma |
MedlinePlus related topics: | Cancer Lymphoma |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma |
Estimated Enrollment: | 60 |
Study Start Date: | February 2003 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
1
Follicular Lymphoma
|
2
Non-follicular Lymphoma
|
This is a prospective observational clinical study of possible infectious disease-associated antigen drive in previously untreated patients with indolent lymphoma (follicular and nonfollicular cohorts).
Eligible patients with a new diagnosis of indolent lymphoma will be enrolled after informed consent. All patients will be tested for possible known infectious diseases that may contribute to antigen drive (H. Pylori; Hepatitis C), as well as for other infectious diseases not yet established as contributing to antigen drive (Borrelia; Chlamydia; and small bowel overgrowth). All patients will have a complete history recorded regarding other possible chronic infections, and an infectious disease consultation, as indicated.
Patients with positive antigen-drive infectious disease studies will be treated as indicated with standard antibiotic regimens and response (both infectious disease as well as lymphoma status)will be documented and recorded.
The primary objective of this study is (1) to evaluate the possible association of infectious diseases in previously untreated patients with indolent lymphoma. The secondary objective of this study is to evaluate possible lymphoma response the in patients treated for positive infectious disease studies; and to evaluate EBV immune responses in these previously untreated patients.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Follicular and non-follicular non-Hodgkin's lymphoma
Inclusion Criteria:
Exclusion Criteria:
United States, New York | |||||
Memorial Sloan-Kettering Cancer Center | |||||
New York, New York, United States, 10065 |
Memorial Sloan-Kettering Cancer Center |
Principal Investigator: | Carol Portlock, MD | Memorial Sloan-Kettering Cancer Center |
Memorial Sloan-Kettering Cancer Center 
![]()   |
Responsible Party: | Memorial Sloan-Kettering Cancer Center ( Carol Portlock, MD ) |
Study ID Numbers: | 03-012 |
First Received: | December 21, 2007 |
Last Updated: | December 21, 2007 |
ClinicalTrials.gov Identifier: | NCT00582270 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
![]() |